AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12118900
Drug: sirolimus 5
RxNorm normalized name: SIROLIMUS 5 mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION [FYARRO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sirolimus 5 mg/day
Trial: 9717677
Drug: OspA vaccine
RxNorm normalized name: OspA protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OspA vaccine (30-microgram dose)
Trial: 2650588
Drug: 10 to
RxNorm normalized name: RE-10 Topical Wash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 to 20 mg oral nifedipine
Trial: 336013
Drug: 25% sodium
RxNorm normalized name: Dextrose 5% and 0.225% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% sodium fluorescein solution
Trial: 336013
Drug: 10% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% sodium fluorescein solution
Trial: 28934528
Drug: Lower altitude
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower altitude laboratory polysomnography (L-PSG)
Trial: 22820718
Drug: Approved dose
RxNorm normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Approved dose of fospropofol (4.875 or 6.5 mg/kg depending on patient subgroup)
Trial: 22820718
Drug: Weight-adjusted dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-adjusted dose of fospropofol
Trial: 22820718
Drug: Approved dose
RxNorm normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Approved dose of fospropofol
Trial: 28394435
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant (OAC) therapy
Trial: 10969261
Drug: Oat cereal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat cereal (24 grams per day, 1.2 ± 0.9 g/kg/d)
Trial: 8771109
Drug: Autovac system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autovac system with calcium binding resin anticoagulant
Trial: 8378945
Drug: Aspirin 650
RxNorm normalized name: aspirin 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 650 mg twice daily
Trial: 29952033
Drug: One-piece implant
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-piece implant system (STM)
Trial: 29952033
Drug: Two-piece implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-piece implant system (BRA)
Trial: 28916304
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of dilute mesenchymal stem cells (MSCs)
Trial: 28916304
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of concentrated mesenchymal stem cells (MSCs)
Trial: 18550961
Drug: C (Caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C (Caffeine 300 mg)
Trial: 18550961
Drug: C +
RxNorm normalized name: Probiotic + Colostrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C + E (Caffeine 300 mg + Ephedra 60 mg)
Trial: 18550961
Drug: P (Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P (Placebo 300 mg)
Trial: 16210886
Drug: Once-daily administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily administration of fluticasone propionate (200 microg at night)
Trial: 16210886
Drug: Twice-daily administration
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily administration of fluticasone propionate (100 microg in the morning and at night)
Trial: 8336527
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium diet (40 mmol of sodium daily)
Trial: 8336527
Drug: High sodium
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High sodium diet (120 mmol of sodium daily)
Trial: 8336527
Drug: K-canrenoate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-canrenoate (200 mg/day increasing to 600 mg)
Trial: 8336527
Drug: Furosemide (25-50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (25-50-100 mg every other day)
Trial: 8336527
Drug: Washout period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Washout period of 7 days from outpatient diuretic regimen
Trial: 29985433
Drug: Selective Triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective Triple Antithrombotic Therapy (TATT)
Trial: 29985433
Drug: Ticagrelor-based Dual
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor-based Dual Antiplatelet Therapy (DAPT)
Trial: 26653111
Drug: GH 1
RxNorm normalized name: Cough 100mg/5ml Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 1 mg/m(2)/d
Trial: 26653111
Drug: GH 2
RxNorm normalized name: ColdCough 2mg-7.5mg-15mg/5ml Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 2 mg/m(2)/d
Trial: 26653111
Drug: GH 1
RxNorm normalized name: Cough 100mg/5ml Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 1 mg/m(2)/d with GnRHa
Trial: 26653111
Drug: GH 2
RxNorm normalized name: ColdCough 2mg-7.5mg-15mg/5ml Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 2 mg/m(2)/d with GnRHa
Trial: 18388038
Drug: Policosanol 10
RxNorm normalized name: policosanol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 10 mg/d
Trial: 11061069
Drug: Intention to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intention to seek treatment for UI
Trial: 8889418
Drug: Aprotinin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin 0.2 mg kg‐1 (group A)
Trial: 8889418
Drug: Aprotinin 0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin 0.7 mg kg‐1 (group B)
Trial: 8889418
Drug: Aprotinin 1
RxNorm normalized name: aprotinin 1.4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin 1 mg kg‐1 (group C)
Trial: 8889418
Drug: Aprotinin 1.4
RxNorm normalized name: aprotinin 1.4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin 1.4 mg kg‐1 (group D)
Trial: 31340849
Drug: Repetitive vascular
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive vascular occlusion stimulus (RVOS) applied twice daily (once on day 1) for up to 10 days or until ICU discharge
Trial: 8155434
Drug: 0.05% clobetasol
RxNorm normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% clobetasol propionate cream
Trial: 22807477
Drug: Individualised dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised dose of oral 17β-oestradiol (5-15 μg/kg per day for 2 years)
Trial: 22807477
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose of oral 17β-oestradiol (0.2 mg daily for the first year, 0.5 mg daily for the second year)
Trial: 21225018
Drug: Fluticasone nasal
RxNorm normalized name: fluticasone nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone nasal spray (200 μg in each nostril) once a day
Trial: 21225018
Drug: Fluticasone nasal
RxNorm normalized name: fluticasone nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone nasal spray (200 μg in each nostril) plus cetrizine (10 mg) orally once a day
Trial: 21225018
Drug: Fluticasone nasal
RxNorm normalized name: fluticasone nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone nasal spray (200 μg in each nostril) plus montelukast (10 mg) orally once a day
Trial: 17681971
Drug: Bilateral superficial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral superficial cervical plexus block with ropivacaine 0.487% plus clonidine 5 microg ml(‐1) (Group RC)
Trial: 15754237
Drug: First treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First treatment with lumbar paravertebral nerve root infiltration
Trial: 526399
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Labetalol + Bethanidine)
Trial: 30606273
Drug: IPS-WFM combination
RxNorm normalized name: IP-2018
DrugBank: IP-2018 (DB19049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPS-WFM combination
Trial: 30606273
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (equally intensive clinical treatment)
Trial: 30448355
Drug: LUS-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LUS-guided treatment strategy
Trial: 30448355
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care treatment strategy
Trial: 7128190
Drug: Benzydamine oral
RxNorm normalized name: benzydamine Oral Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzydamine oral rinse
Trial: 16924985
Drug: Etch and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etch and rinse adhesive systems (SBMP, OS, SB1, G)
Trial: 10908001
Drug: manualized, cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: manualized, cognitive‐behavioral outpatient treatment developed by the Matrix Center in Los Angeles
Trial: 10908001
Drug: treatment approaches
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment approaches currently employed by the treatment sites
Trial: 8700338
Drug: Mepartricin 150,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepartricin 150,000 U (40 mg) once in the evening for 60 days
Trial: 8700338
Drug: Mepartricin 50,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepartricin 50,000 U (13 mg) t.d.s.
Trial: 7058868
Drug: Baseline treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline treatments
Trial: 27029546
Drug: Systemic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic Therapy (ST)
Trial: 22295817
Drug: Abdominal acupuncture
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal acupuncture (treatment at Zhongwan (CV 12), Shangqu (KI 17) on healthy side, Huaroumen (ST 24) on affected side)
Trial: 22295817
Drug: Acupuncture (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (treatment at Jianyu (LI 15), Jianliao (TE 14), Jianzhen (SI 9) on affected side)
Trial: 7753957
Drug: 0.0 mg
RxNorm normalized name: RUXOLITINIB 10.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0 mg nicotine polacrilex
Trial: 7753957
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg nicotine polacrilex
Trial: 7753957
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg nicotine polacrilex
Trial: 7753957
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg nicotine polacrilex
Trial: 7753957
Drug: 4.0 mg
RxNorm normalized name: LORAZEPAM 4.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 mg nicotine polacrilex
Trial: 31568675
Drug: Testosterone (Sustanon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (Sustanon 250 mg)
Trial: 27966406
Drug: Lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle intervention preceding infertility treatment
Trial: 25189222
Drug: PCT-guided antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCT-guided antimicrobial therapy
Trial: 25189222
Drug: Standard antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antimicrobial therapy (control group)
Trial: 17978254
Drug: Number of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of psychotropic medications prescribed
Trial: 15805340
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg lidocaine
Trial: 15805340
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg lidocaine
Trial: 11940288
Drug: Thrombolysis combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolysis combined with anticoagulant therapy
Trial: 11940288
Drug: Pure anticoagulant
RxNorm normalized name: Dream Pure BB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pure anticoagulant therapy
Trial: 11940288
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (combined)
Trial: 9871816
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 or 40 mg/day)
Trial: 9871816
Drug: Amitriptyline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (50 or 100 mg/day)
Trial: 7620114
Drug: Loxoprofen sodium
RxNorm normalized name: loxoprofen sodium dihydrate
DrugBank: Loxoprofen (DB09212)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Loxoprofen sodium 60 mg
Trial: 8436153
Drug: Indomethacin 25
RxNorm normalized name: indomethacin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 25 mg
Trial: 25851052
Drug: TDF 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF 300 mg daily from 30-32 weeks of gestation until 1 month postpartum
Trial: 30930022
Drug: TDF 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF 300 mg daily
Trial: 23303244
Drug: Ringers acetate
RxNorm normalized name: Mimulus ringens whole extract
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ringers acetate (20 ml/kg)
Trial: 23303244
Drug: Hydroxyethyl starch
RxNorm normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl starch 130/0.4 (10 ml/kg)
Trial: 23303244
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Ringers acetate and hydroxyethyl starch
Trial: 20400652
Drug: Metoprolol immediate-release
RxNorm normalized name: metoprolol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol immediate-release (IR) 50 mg with paroxetine
Trial: 20400652
Drug: Metoprolol extended-release
RxNorm normalized name: metoprolol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol extended-release (ER) 100 mg with paroxetine
Trial: 20400652
Drug: Metoprolol immediate-release
RxNorm normalized name: metoprolol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol immediate-release (IR) without paroxetine
Trial: 20400652
Drug: Metoprolol extended-release
RxNorm normalized name: metoprolol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol extended-release (ER) without paroxetine
Trial: 7576170
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion (n = 35)
Trial: 28508838
Drug: Intra-hepatic arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-hepatic arterial weekly high-dose 5-fluorouracil (WHF)
Trial: 28508838
Drug: Continuous venous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous venous infusion of 5-fluorouracil (CVI)
Trial: 21370262
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg pramipexole
Trial: 10828728
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg ropinirole
Trial: 16631247
Drug: Caffeine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (250 mg x 3) with mental stress
Trial: 16631247
Drug: Caffeine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (250 mg x 3) with exercise
Trial: 16631247
Drug: Caffeine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (250 mg x 3) after postexercise meal
Trial: 16631247
Drug: Repeated caffeine
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated caffeine doses throughout the test day
Trial: 8385975
Drug: i.v. magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. magnesium sulphate 1 g h‐1 over 8 h
Trial: 8385975
Drug: NaCl 18
RxNorm normalized name: K+ Chloride 50 MG / NaCl 180 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 18 mg h‐1 (control)
Trial: 3825543
Drug: Cimetidine 1
RxNorm normalized name: cimetidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 1 g daily for 30 days (extended to 3 months for 3 patients)
Trial: 3825543
Drug: Antacids 350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacids 350 mmol daily for 30 days (extended to 3 months for 4 patients)
Trial: 10961748
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium phosphate (NaP) solution
Trial: 27476581
Drug: Camicinal (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camicinal (50 mg)
Trial: 20067974
Drug: Glimepiride up
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride up to 6 mg q.d.
Trial: 18703934
Drug: Lithium (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (starting dose: 400 mg/day)
Trial: 18703934
Drug: Valproate (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valproate (starting dose: 20 mg/kg/day)
Trial: 15307437
Drug: Praziquantel treatment
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel treatment (40 mg/kg) - first treatment
Trial: 15307437
Drug: Praziquantel treatment
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel treatment (40 mg/kg) - second treatment
Trial: 15307437
Drug: Praziquantel treatment
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel treatment (40 mg/kg) - side effects
Trial: 14612482
Drug: Parenteral opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral opioids
Trial: 2862814
Drug: Phenoxybenzamine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenoxybenzamine 20 mg
Trial: 2862814
Drug: Orciprenaline 10
RxNorm normalized name: Orciprenaline 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orciprenaline 10 mg
Trial: 2862814
Drug: Prenalterol 10
RxNorm normalized name: prenalterol
DrugBank: Prenalterol (DB13777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenalterol 10 mg
Trial: 29873684
Drug: Oxaliplatin added
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin added to 5-FU-based chemoradiotherapy and adjuvant chemotherapy in patients aged <60 years
Trial: 29873684
Drug: Oxaliplatin added
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin added to 5-FU-based chemoradiotherapy and adjuvant chemotherapy in patients aged 40-70 years
Trial: 19393850
Drug: Test product
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test product (Integrol(R)) 10 mg tablet
Trial: 19393850
Drug: Reference product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product (Zyprexa(R)) 10 mg tablet
Trial: 15325831
Drug: non-steroidal anti-inflammatory
RxNorm normalized name: Non-steroidal anti-inflammatory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-steroidal anti-inflammatory drugs (naproxen 500 mg twice daily or ibuprofen 800 mg three times daily)
Trial: 15325831
Drug: non-steroidal anti-inflammatory
RxNorm normalized name: Non-steroidal anti-inflammatory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-steroidal anti-inflammatory drugs
Trial: 11215327
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release dihydrocodeine (DHC) 60 mg
Trial: 11215327
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release dihydrocodeine (DHC) 120 mg
Trial: 16756423
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg diazepam
Trial: 30592963
Drug: FOLFOX-6 regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX-6 regimen with L-carnosine (500 mg daily)
Trial: 30592963
Drug: FOLFOX-6 regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX-6 regimen without L-carnosine
Trial: 28477428
Drug: ivacaftor 150
RxNorm normalized name: ivacaftor 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivacaftor 150 mg alone (study A)
Trial: 28477428
Drug: ivacaftor 150
RxNorm normalized name: ivacaftor 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivacaftor 150 mg plus ritonavir 50 mg daily (study B)
Trial: 28477428
Drug: ivacaftor 150
RxNorm normalized name: ivacaftor 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivacaftor 150 mg plus ritonavir 50 mg daily after two weeks of ritonavir 50 mg daily (study C)